Published in Cytotherapy, this review co-authored by Natacha Agabalyan, one of our Associate Lead Scientists, brings together expert perspectives on the quality control and safety considerations needed to translate induced pluripotent stem cell (iPSC)-derived therapies into the clinic.
It explores approaches and emerging technologies for assessing product quality and safety, supporting the safe and consistent clinical development of iPSC-derived therapies.
